Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

BACKGROUND: Benralizumab is an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody. Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year for patients with severe, uncontrolled eosinophilic asthma. OBJECTIVE: We explored whether benra...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Asthma Allergy
Hlavní autoři: FitzGerald, J Mark, Bleecker, Eugene R, Bourdin, Arnaud, Busse, William W, Ferguson, Gary T, Brooks, Laura, Barker, Peter, Martin, Ubaldo J
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6910092/
https://ncbi.nlm.nih.gov/pubmed/31849500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S227170
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky